Plain-English translation of NCT05652673 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether patients with advanced melanoma can safely stop taking —a type of immunotherapy medication—after their tumors shrink or disappear. Currently, patients often continue this medication for many months or years. The study wants to see if stopping early, once the cancer responds well to treatment, is just as effective while reducing side effects.
Long-term immunotherapy can cause significant side effects that affect patients' quality of life. Researchers want to know if shorter treatment—stopping once the tumor responds—can work just as well and cause fewer problems for patients.
You likely qualify if…
You likely don't qualify if…
You would continue your current immunotherapy treatment until your scans show your tumor has shrunk or disappeared. Once that happens, you would join the study and stop taking the medication within 4 weeks. After that, you would have regular follow-up visits with imaging scans and brain MRI to monitor whether your cancer stays controlled without the medication. The study lasts about 9 months from your initial treatment start date.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Netherlands
Sponsor
Erasmus Medical Center
Enrollment target
~80 participants
Started
February 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.